Wikisage, the free encyclopedia of the second generation, is digital heritage
Molnupiravir: Difference between revisions
(Created page with "Molnupiravir (development codes EIDD-2801 and MK-4482) is an investigational antiviral drug for oral administration for the treatment of influenza. It is an N4-hydroxycytidine...") |
|||
| Line 7: | Line 7: | ||
[https://www.nature.com/articles/s41564-020-00835-2 Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets] | [https://www.nature.com/articles/s41564-020-00835-2 Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets] | ||
<references/> | <references/> | ||
==Source== | |||
[https://enwiki.miraheze.org/w/index.php?title=Molnupiravir&oldid=2390 enWiki(Miraheze)] | |||
Revision as of 13:46, 27 January 2021
Molnupiravir (development codes EIDD-2801 and MK-4482) is an investigational antiviral drug for oral administration for the treatment of influenza. It is an N4-hydroxycytidine-donating prodrug, a nucleoside derivative known to be mutagenic that acts against RNA viruses by introducing errors in RNA replication by the viral RNA-dependent RNA polymerase. It also has some activity against coronaviruses such as SARS-CoV, MERS-CoV and SARS-CoV-25, responsible for SARS, MERS and COVID-19 respectively. It was developed at Emory University in Atlanta, Georgia, before being acquired by Ridgeback Biotherapeutics in Miami, Florida, which has partnered with Merck & Co. for further development. [1]
External Links
Coronavirus RNA Proofreading Molecular basis and therapeutic target